Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Gene silencing of SLC5A8 identified by genome-wide methylation profiling in lung cancer.

Park JY, Kim D, Yang M, Park HY, Lee SH, Rincon M, Kreahling J, Plass C, Smiraglia DJ, Tockman MS, Kim SJ.

Lung Cancer. 2013 Mar;79(3):198-204. doi: 10.1016/j.lungcan.2012.11.019. Epub 2012 Dec 27.

2.

Randomized phase II trial of sulindac for lung cancer chemoprevention.

Limburg PJ, Mandrekar SJ, Aubry MC, Ziegler KL, Zhang J, Yi JE, Henry M, Tazelaar HD, Lam S, McWilliams A, Midthun DE, Edell ES, Rickman OB, Mazzone P, Tockman M, Beamis JF, Lamb C, Simoff M, Loprinzi C, Szabo E, Jett J; Cancer Prevention Network.

Lung Cancer. 2013 Mar;79(3):254-61. doi: 10.1016/j.lungcan.2012.11.011. Epub 2012 Dec 20.

3.

Generation of lung adenocarcinoma DNA aptamers for cancer studies.

Jiménez E, Sefah K, López-Colón D, Van Simaeys D, Chen HW, Tockman MS, Tan W.

PLoS One. 2012;7(10):e46222. doi: 10.1371/journal.pone.0046222. Epub 2012 Oct 17.

4.

A new method for lung cancer prognosis via centrosome image feature analysis.

Song D, Zhukov TA, Markov O, Qian W, Tockman MS.

Anal Quant Cytopathol Histpathol. 2012 Aug;34(4):180-8.

PMID:
23016464
5.

Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancers.

Hazelton WD, Goodman G, Rom WN, Tockman M, Thornquist M, Moolgavkar S, Weissfeld JL, Feng Z.

Math Biosci. 2012 Nov;240(1):20-34. doi: 10.1016/j.mbs.2012.05.008. Epub 2012 Jun 15.

6.

Quantificational and statistical analysis of the differences in centrosomal features of untreated lung cancer cells and normal cells.

Song D, Fedorenko I, Pensky M, Qian W, Tockman MS, Zhukov TA.

Anal Quant Cytol Histol. 2010 Oct;32(5):280-90.

PMID:
22043504
7.

Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials.

Doria-Rose VP, Marcus PM, Miller AB, Bergstralh EJ, Mandel JS, Tockman MS, Prorok PC.

Clin Trials. 2010 Feb;7(1):69-77. doi: 10.1177/1740774509356461.

PMID:
20156958
8.
9.

Respiratory effects of household exposures to tobacco smoke and gas cooking.

Comstock GW, Meyer MB, Helsing KJ, Tockman MS.

Am J Epidemiol. 2008 Oct 1;168(7):810-5. doi: 10.1093/aje/kwn269.

PMID:
18820274
10.

Dietary n-3 polyunsaturated acids and smoking-related chronic obstructive pulmonary disease.

Shahar E, Folsom AR, Melnick SL, Tockman MS, Comstock GW, Gennaro V, Higgins MW, Sorlie PD, Ko WJ, Szklo M; Atherosclerosis Risk in Communities Study Investigators.

Am J Epidemiol. 2008 Oct 1;168(7):796-801. doi: 10.1093/aje/kwn322.

PMID:
18820272
11.

Computed tomography screening and lung cancer outcomes.

Bach P, Jett J, Pastorino U, Tockman M, Swensen S, Begg C.

Rev Port Pneumol. 2007 Nov-Dec;13(6):888-90. doi: 10.1016/S0873-2159(15)30384-6. English, Portuguese. No abstract available.

12.

Computerized analysis of cellular features and biomarkers for cytologic diagnosis of early lung cancer.

Qian W, Zhukov T, Song D, Tockman MS.

Anal Quant Cytol Histol. 2007 Apr;29(2):103-11.

PMID:
17484274
13.

Computed tomography screening and lung cancer outcomes.

Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB.

JAMA. 2007 Mar 7;297(9):953-61. Erratum in: JAMA. 2007 Aug 1;298(5):518.

PMID:
17341709
14.

CpG island hypermethylation profiling of lung cancer using restriction landmark genomic scanning (RLGS) analysis.

Park J, Brena RM, Gruidl M, Zhou J, Huang T, Plass C, Tockman MS.

Cancer Biomark. 2005;1(2-3):193-200.

PMID:
17192040
15.

Genetic analysis of microsomal epoxide hydrolase gene and its association with lung cancer risk.

Park JY, Chen L, Elahi A, Lazarus P, Tockman MS.

Eur J Cancer Prev. 2005 Jun;14(3):223-30.

16.

Polymorphisms in the promoter region of neutrophil elastase gene and lung cancer risk.

Park JY, Chen L, Lee J, Sellers T, Tockman MS.

Lung Cancer. 2005 Jun;48(3):315-21. Epub 2005 Jan 20.

17.

Improbable estimate of lung cancer mortality from screening trials.

Tockman MS.

J Clin Oncol. 2005 Mar 20;23(9):2106-7; author reply 2107-8. No abstract available.

PMID:
15774802
18.

Polymorphisms for microsomal epoxide hydrolase and genetic susceptibility to COPD.

Park JY, Chen L, Wadhwa N, Tockman MS.

Int J Mol Med. 2005 Mar;15(3):443-8.

19.

Data mining techniques for cancer detection using serum proteomic profiling.

Li L, Tang H, Wu Z, Gong J, Gruidl M, Zou J, Tockman M, Clark RA.

Artif Intell Med. 2004 Oct;32(2):71-83. Review.

PMID:
15364092
20.

The human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) DNA repair enzyme and its association with lung cancer risk.

Park J, Chen L, Tockman MS, Elahi A, Lazarus P.

Pharmacogenetics. 2004 Feb;14(2):103-9. Review.

PMID:
15077011
21.

A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest.

Bepler G, Goodridge Carney D, Djulbegovic B, Clark RA, Tockman M.

Cancer Control. 2003 Jul-Aug;10(4):306-14. Review.

PMID:
12915809
22.

Epigenetic down-regulation of death-associated protein kinase in lung cancers.

Toyooka S, Toyooka KO, Miyajima K, Reddy JL, Toyota M, Sathyanarayana UG, Padar A, Tockman MS, Lam S, Shivapurkar N, Gazdar AF.

Clin Cancer Res. 2003 Aug 1;9(8):3034-41.

23.

Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry.

Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS.

Lung Cancer. 2003 Jun;40(3):267-79.

PMID:
12781425
24.

Cost-effectiveness of screening for lung cancer.

Chirikos TN, Hazelton T, Tockman M, Clark R.

JAMA. 2003 May 14;289(18):2358; author reply 2358-9. No abstract available.

PMID:
12746351
25.

Gene-environment interactions between the codon 194 polymorphism of XRCC1 and antioxidants influence lung cancer risk.

Ratnasinghe DL, Yao SX, Forman M, Qiao YL, Andersen MR, Giffen CA, Erozan Y, Tockman MS, Taylor PR.

Anticancer Res. 2003 Jan-Feb;23(1B):627-32.

PMID:
12680158
26.
27.

Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations.

Field JK, Brambilla C, Caporaso N, Flahault A, Henschke C, Herman J, Hirsch F, Lachmann P, Lam S, Maier S, Montuenga LM, Mulshine J, Murphy M, Pullen J, Spitz M, Tockman M, Tyndale R, Wistuba I, Youngson J.

Int J Oncol. 2002 Aug;21(2):369-73. Review.

PMID:
12118333
28.

Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures.

Toyooka S, Fukuyama Y, Wistuba II, Tockman MS, Minna JD, Gazdar AF.

Clin Cancer Res. 2002 Jul;8(7):2292-7.

29.

Screening for lung cancer with CT: a preliminary cost-effectiveness analysis.

Chirikos TN, Hazelton T, Tockman M, Clark R.

Chest. 2002 May;121(5):1507-14.

PMID:
12006436
30.

Diagnosis of roentgenographically occult lung cancer by sputum cytology.

Petty TL, Tockman MS, Palcic B.

Clin Chest Med. 2002 Mar;23(1):59-64. Review.

PMID:
11901920
31.

Lung cancer evolution to preinvasive management.

Mulshine JL, Cuttitta F, Tockman MS, De Luca LM.

Clin Chest Med. 2002 Mar;23(1):37-48. Review.

PMID:
11901918
32.

Moving to the routine management of pre symptomatic lung cancer.

Mulshine JL, Hong S, Martínez A, Tauler J, Avis I, Tockman MS, De Luca LM, Placke ME, Cuttitta F.

Lung Cancer. 2001 Dec;34 Suppl 2:S1-5.

PMID:
11720735
33.

Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer.

Zhou J, Nong L, Wloch M, Cantor A, Mulshine JL, Tockman MS.

Lung Cancer. 2001 Dec;34(3):341-50.

PMID:
11714531
34.

Loss of heterogeneous ribonucleoprotein A(2)/B(1) expression in thyroid neoplasms.

Bidot P, Morgan M, Zhukov T, Tannenbaum M, Tockman MS.

Endocr Pract. 2001 May-Jun;7(3):157-61.

PMID:
11421561
35.

Lung cancer: chemoprevention and intermediate effect markers.

Tockman MS.

IARC Sci Publ. 2001;154:257-70. Review.

PMID:
11220665
36.

Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk.

Ratnasinghe D, Yao SX, Tangrea JA, Qiao YL, Andersen MR, Barrett MJ, Giffen CA, Erozan Y, Tockman MS, Taylor PR.

Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):119-23.

37.

Considerations in developing successful, population-based molecular screening and prevention of lung cancer.

Mulshine JL, De Luca LM, Dedrick RL, Tockman MS, Webster R, Placke ME.

Cancer. 2000 Dec 1;89(11 Suppl):2465-7. Review.

PMID:
11147628
38.

Microsatellite instability at AAAG repeat sequences in respiratory tract cancers.

Xu L, Chow J, Bonacum J, Eisenberger C, Ahrendt SA, Spafford M, Wu L, Lee SM, Piantadosi S, Tockman MS, Sidransky D, Jen J.

Int J Cancer. 2001 Jan 15;91(2):200-4.

39.

The early detection of occult lung cancer.

Tockman MS, Mulshine JL.

Chest Surg Clin N Am. 2000 Nov;10(4):737-49. Review.

PMID:
11091923
40.

Serum carotenoids are associated with increased lung cancer risk among alcohol drinkers, but not among non-drinkers in a cohort of tin miners.

Ratnasinghe D, Forman MR, Tangrea JA, Qiao Y, Yao SX, Gunter EW, Barrett MJ, Giffen CA, Erozan Y, Tockman MS, Taylor PR.

Alcohol Alcohol. 2000 Jul-Aug;35(4):355-60.

PMID:
10906000
41.

Advances in sputum analysis for screening and early detection of lung cancer.

Tockman MS.

Cancer Control. 2000 Jan-Feb;7(1):19-24. Review.

PMID:
10740657
42.

Serum tocopherols, selenium and lung cancer risk among tin miners in China.

Ratnasinghe D, Tangrea JA, Forman MR, Hartman T, Gunter EW, Qiao YL, Yao SX, Barett MJ, Giffen CA, Erozan Y, Tockman MS, Taylor PR.

Cancer Causes Control. 2000 Feb;11(2):129-35.

PMID:
10710196
43.

Efficacy of two sputum collection techniques in patients with air flow obstruction.

Kennedy TC, Proudfoot SP, Piantadosi S, Wu L, Saccomanno G, Petty TL, Tockman MS.

Acta Cytol. 1999 Jul-Aug;43(4):630-6.

PMID:
10432886
44.

Docosahexaenoic acid and smoking-related chronic obstructive pulmonary disease. The Atherosclerosis Risk in Communities Study Investigators.

Shahar E, Boland LL, Folsom AR, Tockman MS, McGovern PG, Eckfeldt JH.

Am J Respir Crit Care Med. 1999 Jun;159(6):1780-5.

PMID:
10351918
45.

Demographic and anthropometric correlates of maximum inspiratory pressure: The Atherosclerosis Risk in Communities Study.

Carpenter MA, Tockman MS, Hutchinson RG, Davis CE, Heiss G.

Am J Respir Crit Care Med. 1999 Feb;159(2):415-22.

PMID:
9927352
46.

Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression.

Tockman MS, Mulshine JL, Piantadosi S, Erozan YS, Gupta PK, Ruckdeschel JC, Taylor PR, Zhukov T, Zhou WH, Qiao YL, Yao SX.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2237-46.

47.

Longitudinal change in forced expiratory volume in healthy, non-smoking men and women: The Baltimore Longitudinal Study of Aging.

Pearson JD, Kao SY, Brant LJ, Metter EJ, Tockman MS, Fozard JL.

Am J Hum Biol. 1998;10(4):471-481. doi: 10.1002/(SICI)1520-6300(1998)10:4<471::AID-AJHB7>3.0.CO;2-J. No abstract available.

PMID:
28561473
48.

Risk factors and early detection of lung cancer in a cohort of Chinese tin miners.

Qiao YL, Taylor PR, Yao SX, Erozan YS, Luo XC, Barrett MJ, Yan QY, Giffen CA, Huang SQ, Maher MM, Forman MR, Tockman MS.

Ann Epidemiol. 1997 Nov;7(8):533-41.

PMID:
9408549
49.

A case-cohort study of an early biomarker of lung cancer in a screening cohort of Yunnan tin miners in China.

Qiao YL, Tockman MS, Li L, Erozan YS, Yao SX, Barrett MJ, Zhou WH, Giffen CA, Luo XC, Taylor PR.

Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):893-900.

50.

Sputum screening by quantitative microscopy: a new dawn for detection of lung cancer?

Tockman MS, Mulshine JL.

Mayo Clin Proc. 1997 Aug;72(8):788-90. No abstract available.

PMID:
9276609

Supplemental Content

Loading ...
Support Center